The engineered IL2 cytokine bempegaldesleukin fell flat in multiple late-stage clinical studies, prompting its developers—Nektar Therapeutics and Bristol Myers Squibb—to halt its clinical development. However, a pipeline of diverse IL2-based therapies may yet succeed.

You do not currently have access to this content.